Connection

Co-Authors

This is a "connection" page, showing publications co-authored by MITCHELL FREDERICK and VLAD SANDULACHE.
Connection Strength

3.914
  1. Reliable RNA-seq analysis from FFPE specimens as a means to accelerate cancer-related health disparities research. PLoS One. 2025; 20(4):e0321631.
    View in: PubMed
    Score: 0.917
  2. High expression of oxidative phosphorylation genes predicts improved survival in squamous cell carcinomas of the head and neck and lung. Sci Rep. 2020 04 14; 10(1):6380.
    View in: PubMed
    Score: 0.648
  3. NOTCH1 acts as a tumor suppressor that induces early differentiation in head and neck cancer. JCI Insight. 2026 Jun 08; 11(11).
    View in: PubMed
    Score: 0.246
  4. Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting. Br J Cancer. 2025 Dec; 133(12):1802-1814.
    View in: PubMed
    Score: 0.237
  5. Tobacco smoke exposure is a driver of altered oxidative stress response and immunity in head and neck cancer. J Transl Med. 2025 Apr 05; 23(1):403.
    View in: PubMed
    Score: 0.229
  6. Recurrent Oropharyngeal Squamous Cell Carcinomas Maintain Anti-tumor Immunity and Multinucleation Levels Following Completion of Radiation. Head Neck Pathol. 2023 Dec; 17(4):952-960.
    View in: PubMed
    Score: 0.208
  7. Recurrent oropharyngeal squamous cell carcinomas maintain anti-tumor immunity and multinucleation levels following completion of radiation. Res Sq. 2023 Aug 21.
    View in: PubMed
    Score: 0.204
  8. Machine learning driven index of tumor multinucleation correlates with survival and suppressed anti-tumor immunity in head and neck squamous cell carcinoma patients. Oral Oncol. 2023 08; 143:106459.
    View in: PubMed
    Score: 0.202
  9. Evolution of cisplatin resistance through coordinated metabolic reprogramming of the cellular reductive state. Br J Cancer. 2023 06; 128(11):2013-2024.
    View in: PubMed
    Score: 0.199
  10. Glutathione peroxidase 2 is a metabolic driver of the tumor immune microenvironment and immune checkpoint inhibitor response. J Immunother Cancer. 2022 08; 10(8).
    View in: PubMed
    Score: 0.190
  11. Oropharyngeal cancer outcomes correlate with p16 status, multinucleation and immune infiltration. Mod Pathol. 2022 08; 35(8):1045-1054.
    View in: PubMed
    Score: 0.184
  12. Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples. Am J Pathol. 2011 Feb; 178(2):548-71.
    View in: PubMed
    Score: 0.086
  13. Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. Cancer. 2011 Jul 01; 117(13):2926-38.
    View in: PubMed
    Score: 0.085
  14. Targeted suppression of SPP1 inhibits tumor invasion and metastasis in NRF2 hyperactivated cisplatin resistant HNSCC. J Transl Med. 2026 May 22.
    View in: PubMed
    Score: 0.062
  15. Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2025 Oct 01; 31(19):4184-4195.
    View in: PubMed
    Score: 0.059
  16. Targeted suppression of SPP1 inhibits tumor invasion and metastasis in NRF2 hyperactivated cisplatin resistant HNSCC. bioRxiv. 2025 Jun 01.
    View in: PubMed
    Score: 0.058
  17. FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner. Clin Cancer Res. 2024 01 05; 30(1):187-197.
    View in: PubMed
    Score: 0.052
  18. Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2023 04 03; 29(7):1344-1359.
    View in: PubMed
    Score: 0.050
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.